Tesla: Q1 Consensus Estimates

Tesla (NASDAQ: TSLA) will be reporting their first quarter financial results on April 26th after market close. Analysts have a consensus $650.81 12-month price target on the company, via a total of 38 analysts, with nine analysts having strong buy ratings. Six analysts meanwhile have buy ratings, 12 have hold ratings, seven analysts have a sell rating and four have strong sells on the company. The street high comes from Piper Sandler with a $1,200 price target, and the lowest target sits at $67 from GLJ Research.

21 analysts have revenue estimates for the first quarter. The mean revenue estimate between all 21 analysts is $10.62 billion; this number has been revised upwards from $10.3 billion at the start of the year. The highest revenue estimate is $12.34 billion, while the lowest is $8.2 billion.

Onto EBITDA estimates, there are currently only 8 analysts who have first-quarter EBITDA estimates. The mean is currently $1.8 billion, with this number having been revised down from $2 billion at the start of the year. The street high estimate currently sits at $2 billion in EBITDA and the lowest is $1.2 billion.

Analysts estimate that quarterly earnings per share will come in at $0.85, with this number being slightly revised down from $0.91 at the start of the year. Street high is $0.97 and the lowest estimate is $0.46 per share for the quarter.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Building the Next 500,000-Ounce Gold Producer | Stephen Soock – Heliostar Metals

This Gold Explorer Is Making Its Biggest Bet | Brian Miller – Astra Exploration

This Gold Discovery Just Keeps Getting Bigger | Roger Rosmus – Goliath Resources

Recommended

This Gold Discovery Just Keeps Getting Bigger | Roger Rosmus – Goliath Resources

Cardiol Expands MAVERIC Trial to Up to 150 Patients After Reaching Enrollment Target Early

Related News

Osisko Gold: Haywood Upgrades Price Target From $19.75 to $22.25

Osisko Gold Royalties (TSX: OR) (NYSE: OR) provided an update on their deliveries received this...

Friday, July 10, 2020, 03:36:35 PM

Tesla Shares Continue Their Descent As Chinese Sales Slump

Tesla shares continued their nosedive on Wednesday, after data from China showed a significant drop...

Thursday, May 20, 2021, 11:42:00 AM

Start-Up EV Maker Rivian Files Paperwork for IPO

On August 27, the private start-up electric vehicle manufacturer Rivian submitted a widely anticipated confidential...

Tuesday, August 31, 2021, 03:37:00 PM

MicroStrategy: Canaccord Initiates With $920 Price Target

On Friday, Canaccord Genuity initiated coverage on MicroStrategy (NASDAQ: MSTR) with a $920 price target...

Monday, April 12, 2021, 04:03:00 PM

Tesla Ordered to Refund Lawyer $10,600 for Undelivered Self-Driving Feature

An arbitrator has ordered Tesla Inc. (Nasdaq: TSLA) to refund $10,600 to a Washington state...

Friday, July 11, 2025, 03:20:00 PM